JP2022540806A5 - - Google Patents
Info
- Publication number
- JP2022540806A5 JP2022540806A5 JP2021578268A JP2021578268A JP2022540806A5 JP 2022540806 A5 JP2022540806 A5 JP 2022540806A5 JP 2021578268 A JP2021578268 A JP 2021578268A JP 2021578268 A JP2021578268 A JP 2021578268A JP 2022540806 A5 JP2022540806 A5 JP 2022540806A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- antibody
- identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025181128A JP2026026087A (ja) | 2019-07-19 | 2025-10-27 | 免疫調節抗体およびその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962876579P | 2019-07-19 | 2019-07-19 | |
| US201962876580P | 2019-07-19 | 2019-07-19 | |
| US62/876,579 | 2019-07-19 | ||
| US62/876,580 | 2019-07-19 | ||
| US201962878265P | 2019-07-24 | 2019-07-24 | |
| US62/878,265 | 2019-07-24 | ||
| PCT/US2020/042668 WO2021016128A1 (en) | 2019-07-19 | 2020-07-17 | Immunomodulatory antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025181128A Division JP2026026087A (ja) | 2019-07-19 | 2025-10-27 | 免疫調節抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022540806A JP2022540806A (ja) | 2022-09-20 |
| JP2022540806A5 true JP2022540806A5 (cg-RX-API-DMAC7.html) | 2023-07-26 |
| JP7852904B2 JP7852904B2 (ja) | 2026-04-28 |
Family
ID=74193810
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021578268A Active JP7852904B2 (ja) | 2019-07-19 | 2020-07-17 | 免疫調節抗体およびその使用方法 |
| JP2025181128A Pending JP2026026087A (ja) | 2019-07-19 | 2025-10-27 | 免疫調節抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025181128A Pending JP2026026087A (ja) | 2019-07-19 | 2025-10-27 | 免疫調節抗体およびその使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US11634501B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4004051A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7852904B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220035452A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114423787B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020315878A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022000876A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3147103A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL289829A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022000726A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12022550141A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202116809A (cg-RX-API-DMAC7.html) |
| UY (1) | UY38797A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021016128A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11634501B2 (en) | 2019-07-19 | 2023-04-25 | Oncoresponse, Inc. | Immunomodulatory antibodies and methods of use thereof |
| US20240084029A1 (en) * | 2021-01-20 | 2024-03-14 | Oncoresponse, Inc. | Use of immunomodulatory antibodies to treat fibrotic diseases |
| MX2023008485A (es) * | 2021-01-20 | 2023-07-28 | Oncoresponse Inc | Anticuerpos inmunomoduladores y usos de estos. |
| US11845791B2 (en) * | 2021-03-08 | 2023-12-19 | Medimmune, Llc | Antibodies directed against GDF-15 |
| WO2023034762A2 (en) * | 2021-08-30 | 2023-03-09 | Obi Pharma, Inc. | Bispecific dendritic cell engager and uses thereof |
| WO2023034963A2 (en) * | 2021-09-03 | 2023-03-09 | Oncoresponse, Inc. | Combinations of immunotherapies and uses thereof |
| AU2022426854A1 (en) * | 2021-12-31 | 2024-06-13 | The Trustees Of Columbia University In The City Of New York | Bispecific molecules to target the first cell |
| EP4615480A1 (en) * | 2022-11-07 | 2025-09-17 | Alector LLC | Uses of siglec-9 ecd fusion molecules in cancer treatment |
| JP2026519901A (ja) * | 2023-01-27 | 2026-06-19 | ヴィーアイビー ヴィーゼットヴィー | Cd163結合複合体 |
| AU2024391672A1 (en) | 2023-11-30 | 2026-05-21 | Oncospear Aps | Anti-cd163 antibodies with improved adcc capabilities |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| DE69308573T2 (de) | 1992-08-17 | 1997-08-07 | Genentech Inc | Bispezifische immunoadhesine |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| DE60140069D1 (de) | 2000-10-16 | 2009-11-12 | Cytoguide Aps | Funktion eines haptoglobin-hämoglobin-rezeptors und anwendungszwecke dafür |
| AU2003243058A1 (en) | 2002-05-27 | 2003-12-12 | Bioceros B.V. | Methods for using the cd163 pathway for modulating an immune response |
| EP1367393A1 (en) * | 2002-05-27 | 2003-12-03 | MacroZyme B.V. | Methods for using the CD 163 pathway for modulating an immune response |
| AU2004204462B2 (en) | 2003-01-09 | 2012-03-08 | Macrogenics, Inc. | Dual expression vector system for antibody expression in bacterial and mammalian cells |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| US8053569B2 (en) | 2005-10-07 | 2011-11-08 | Armagen Technologies, Inc. | Nucleic acids encoding and methods of producing fusion proteins |
| GB0917044D0 (en) * | 2009-09-29 | 2009-11-18 | Cytoguide As | Agents, uses and methods |
| CA2780221A1 (en) * | 2009-11-04 | 2011-05-12 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
| ES2905545T3 (es) | 2010-01-06 | 2022-04-11 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática |
| EP2632955A1 (en) * | 2010-10-26 | 2013-09-04 | Technion Research & Development Foundation Ltd. | Antibodies which bind soluble t-cell receptor ligands |
| KR102011156B1 (ko) | 2011-01-06 | 2019-08-16 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
| KR102119840B1 (ko) | 2011-07-11 | 2020-06-09 | 아이크노스 사이언스 에스. 아. | Ox40에 결합하는 항체 및 이들의 용도 |
| WO2013167883A1 (en) | 2012-05-07 | 2013-11-14 | The University Court Of The University Of Aberdeen | Single domain binding molecule |
| EP2948478B1 (en) | 2013-01-25 | 2019-04-03 | Amgen Inc. | Antibodies targeting cdh19 for melanoma |
| AU2014213009B2 (en) | 2013-02-01 | 2019-01-03 | Kira Biotech Pty Limited | Anti-CD83 antibodies and use thereof |
| AU2014374055B2 (en) * | 2013-12-30 | 2018-11-08 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| PL3151921T3 (pl) | 2014-06-06 | 2020-02-28 | Bristol-Myers Squibb Company | Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania |
| WO2017010874A1 (en) | 2015-07-10 | 2017-01-19 | Merus N.V. | Human cd3 binding antibody |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗angptl8抗體及其用途 |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| KR101787485B1 (ko) | 2015-12-30 | 2017-11-15 | 재단법인 의약바이오컨버젼스연구단 | 재조합 picp 단백질 및 이에 특이적으로 결합하는 항체의 제조방법 |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| US11596699B2 (en) | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
| EP3491387A1 (en) | 2016-07-28 | 2019-06-05 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods of treatement of cancer disease by targetting tumor associated macrophage |
| WO2018090144A1 (en) | 2016-11-17 | 2018-05-24 | Innovative Targeting Solutions Inc. | Chimeric receptors, biosensor host cells and methods/uses thereof |
| CN110036029A (zh) | 2016-11-17 | 2019-07-19 | 瑞泽恩制药公司 | 用抗angptl8抗体处理肥胖的方法 |
| CA3049791A1 (en) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| WO2019126194A1 (en) | 2017-12-18 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Angptl8 assay and uses thereof |
| CN118271444A (zh) | 2017-12-19 | 2024-07-02 | 瑟罗泽恩奥普瑞汀公司 | Wnt替代分子和其用途 |
| SG10201801219VA (en) | 2018-02-13 | 2019-09-27 | Agency Science Tech & Res | Anti-HER2 Antibodies |
| CN112424358B (zh) | 2018-06-26 | 2025-07-01 | 协和麒麟株式会社 | 与细胞粘附分子3结合的抗体 |
| WO2020018434A1 (en) | 2018-07-17 | 2020-01-23 | Scripps Health | Compositions and methods for disrupting a macrophage network |
| WO2020058372A1 (en) | 2018-09-19 | 2020-03-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy |
| US11634501B2 (en) | 2019-07-19 | 2023-04-25 | Oncoresponse, Inc. | Immunomodulatory antibodies and methods of use thereof |
| WO2023034963A2 (en) | 2021-09-03 | 2023-03-09 | Oncoresponse, Inc. | Combinations of immunotherapies and uses thereof |
-
2020
- 2020-07-17 US US17/597,706 patent/US11634501B2/en active Active
- 2020-07-17 EP EP20843950.5A patent/EP4004051A4/en active Pending
- 2020-07-17 AU AU2020315878A patent/AU2020315878A1/en not_active Abandoned
- 2020-07-17 JP JP2021578268A patent/JP7852904B2/ja active Active
- 2020-07-17 MX MX2022000726A patent/MX2022000726A/es unknown
- 2020-07-17 PH PH1/2022/550141A patent/PH12022550141A1/en unknown
- 2020-07-17 WO PCT/US2020/042668 patent/WO2021016128A1/en not_active Ceased
- 2020-07-17 KR KR1020227005069A patent/KR20220035452A/ko not_active Ceased
- 2020-07-17 CN CN202080065955.9A patent/CN114423787B/zh active Active
- 2020-07-17 CA CA3147103A patent/CA3147103A1/en active Pending
- 2020-07-17 BR BR112022000876A patent/BR112022000876A2/pt not_active IP Right Cessation
- 2020-07-20 TW TW109124493A patent/TW202116809A/zh unknown
- 2020-07-20 UY UY0001038797A patent/UY38797A/es not_active Application Discontinuation
- 2020-07-22 US US16/935,814 patent/US11034770B2/en active Active
-
2021
- 2021-04-22 US US17/302,032 patent/US11827715B2/en active Active
-
2022
- 2022-01-13 IL IL289829A patent/IL289829A/en unknown
-
2023
- 2023-03-17 US US18/185,736 patent/US12195549B2/en active Active
- 2023-10-20 US US18/491,682 patent/US20240239914A1/en not_active Abandoned
-
2025
- 2025-10-22 US US19/366,290 patent/US20260103535A1/en active Pending
- 2025-10-27 JP JP2025181128A patent/JP2026026087A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102470294B1 (ko) | 암을 치료하기 위한 항-pd1 항체 및 방사선의 조합 | |
| AU2014351308B2 (en) | Compositions comprising anti-CEACAM1 and anti-PD antibodies for cancer therapy | |
| KR20220007593A (ko) | 암 치료에서의 효능 강화를 위한 pd-1 억제제와 lag-3 억제제의 병용 | |
| JP2019515008A5 (cg-RX-API-DMAC7.html) | ||
| CN108602889A (zh) | 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体 | |
| Hebb et al. | Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression | |
| KR102314003B1 (ko) | 종양성 질병들에 대한 치료 | |
| WO2021068196A1 (en) | Methods of using il-33 protein in treating cancers | |
| JP2022513421A5 (cg-RX-API-DMAC7.html) | ||
| US20250282864A1 (en) | Subcutaneous administration of cd19-binding t cell engagers | |
| WO2023115033A2 (en) | Use of dual cytokine fusion proteins comprising il-10 and adoptive cell therapies or bispecific t-cell engagers to treat cancer | |
| CN111166878B (zh) | 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途 | |
| US20250367285A1 (en) | Methods of treating melanoma using tebentafusp and immune checkpoint inhibitors | |
| KR20250155054A (ko) | 흑색종 치료에서의 효능 강화를 위한 pd-1 억제제와 lag-3 억제제의 병용 | |
| KR20250117487A (ko) | 항-cd30 항체 약물 콘주게이트 요법의 부작용을 감소시키는 방법 | |
| WO2024041652A1 (en) | Methods of cancer treatment | |
| TW202515613A (zh) | 用於治療前列腺癌之方法 | |
| RU2771759C2 (ru) | Антитела против pd-1 для лечения рака легких | |
| US20240010740A1 (en) | Combination immunotherapy of il-15 and cd40 agonist in cancer treatment | |
| TH2001007178A (th) | แอนติ-PD-1 แอนติบอดีและไบสเปซิฟิกแอนติ-CD3 x MUC16 แอนติบอดีสำหรับการผลิตตัวยาสำหรับการบำบัดหรือการยับยั้งการเจริญของเนื้องอกที่มีการแสดงออก MUC16 | |
| AR133888A1 (es) | ANTICUERPOS IL-5R-a PARA EL TRATAMIENTO DE LA GRANULOMATOSIS EOSINOFÍLICA CON POLIANGITIS | |
| EA040891B1 (ru) | Способы лечения или ингибирования роста плоскоклеточной карциномы кожи с помощью антитела против pd-1 |